SUBSCRIBE
SUBSCRIBE

RadioMedix

IN THE PRESS
Press Releases
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
September 12, 2024
 · 
10 min read
Policy
RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedixTM in gastroenteropancreatic neuroendocrine tumors First Targeted Alpha Therapy to receive a Breakthrough Therapy Designation
February 12, 2024
 · 
5 min read
Drug Development
RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers
May 16, 2023
 · 
5 min read
Deals
RadioMedix Inc. Announces the Acquisition of its 225Ac-PSMA I&T program, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate Cancer, by Fusion Pharmaceuticals Inc.
February 15, 2023
 · 
4 min read
Lone Star Bio
RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH
November 15, 2022
 · 
4 min read
Business
RadioMedix announces a $40 million Series A financing for the advancement of novel Targeted Alpha Therapy platform and diagnostic companion radiopharmaceuticals to address unmet needs in oncology;
October 7, 2022
 · 
4 min read
Business
Radiomedix and Orano Med Announce the Initiation of the Phase II Multi-Center Clinical Trial of Alphamedix™ for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers
January 3, 2022
 · 
4 min read
Lone Star Bio
RADIOMEDIX AWARDED $2.0 M NCI SBIR DIRECT-TO-PHASE II GRANT TO DEVELOP DRUG FOR TARGETED ALPHA-EMITTER THERAPY
November 18, 2021
 · 
2 min read
FDA
Vect-Horus and RadioMedix Announce FDA Approval of Exploratory IND of Diagnostic 68 Ga-RMX-VH in Glioblastoma Multiforme
July 8, 2021
 · 
3 min read
Lone Star Bio
RadioMedix wins 2020 TechConnect Innovation Award and pitched at Virtual TechConnect Business Summit
January 4, 2021
 · 
3 min read
Load More
JOBS